Search
ReviR Therapeutics' RTX-117 Drug Candidate Gains US FDA Orphan Drug Designation
2025-10-13 /
Read about 0 minute
Author：小编
ReviR Therapeutics has made an announcement stating that its small-molecule drug candidate, RTX-117, has been granted Orphan Drug Designation by the US Food and Drug Administration (FDA). This designation is specifically for the treatment of Charcot-Marie-Tooth disease. The company anticipates that RTX-117 will enter Phase I clinical trials in the first quarter of 2026. These trials will be designed to assess the drug's safety, tolerability, and pharmacokinetic properties in healthy volunteers. Following the completion of the Phase I trials, subsequent clinical trials (Phase Ib/IIa) targeting patients with Charcot-Marie-Tooth disease will proceed as scheduled.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
